UN
wavering

The fight against cancer is our life’s work. We’re united by a shared purpose and fueled by our determination to maximize the therapeutic potential of T cells for cancers.

PIONEERS IN CAR T THERAPY

For over 30 years, Dr. Carl June and his team have been leaders in the field of immunological research, with a particular focus on the development of novel immune cell therapies. After developing the first CAR* T cells for HIV in the 1990s, they turned their attention to cancer, which helped lead to the first FDA-approved CAR-T therapy, for hematologic cancers.

At Tmunity, our scientific co-founders’ dedication, expertise, and collaborative approach has positioned the company to advance T cell medicine for all cancers.

*CAR = chimeric antigen receptor.

view Collaboration(s)

TMUNITY - PENN COLLABORATION

Tmunity and the Center for Cellular Immunotherapies at the University of Pennsylvania, led by Carl June, MD, have a unique collaborative relationship that infuses our company with the innovative spirit of an academic research center.

The foundational collaboration, announced in 2015, includes options and license(s) to certain cell engineering and manufacturing technologies, invented and developed in Penn laboratories with deep domain expertise in cell therapies. This partnership enables Tmunity to efficiently apply cutting-edge insights gained in the labs to further the development of next generation T cell therapies for various cancers and facilitate their rapid clinical testing.

view founders

scientific founders

Carl H. June, MD

Scientific Founder

It is everything, to see a kid die of cancer, it breaks your heart. It motivates all of us, every day.

view bio

Bruce Levine, PhD

Scientific Founder

We have the experience, the procedures, and the facilities to establish T cell therapy as a new pillar of medicine.

view bio

James L. Riley, PhD

Scientific Founder

We’ve trained the immune system to recognize and kill tumor cells.

view bio

Anne Chew, PhD

Scientific Founder

We call our modified T cells ‘serial killers’—each one has the potential to kill over a thousand different tumor cells.

view bio

YANGBING ZHAO, MD, PhD

CO-FOUNDER, CHAIRMAN, AND CSO OF UTC THERAPEUTICS

view bio
view Executive Team

Executive Team

Sujay Kango

President & Chief Executive Officer

We are driven to completely transform the future of CAR-T therapies and make cures a reality for patients living with cancer.

view bio

Vijay Reddy Peddareddigari, MD

Executive Vice President, Chief Research & Development Officer

Our collective faith in the power of T cells drives our passion and our urgency—we know we have something.

view bio

Karen chagin, md

Senior Vice President, Chief medical officer

At Tmunity, we are united by the fact that we all care deeply about the patients.

view bio
View Board
Of Directors

board of directors

Beth Seidenberg, MD

Non-executive Chairwoman at Tmunity
Managing Director, Westlake Village BioPartners

view bio

Sujay Kango

President & Chief Executive Officer

view bio

Jorge Conde

General Partner, Andreessen Horowitz

view bio

Patrick Gray

Board member & Audit Committee Chair, Dicerna Pharmaceuticals, Inc.

view bio

Judith Li

Partner, Lilly Asia Ventures

view bio

Garry Nicholson

Board Member & Chair of G1 Therapeutics

view bio

Sean Parker

Founder and Chairman of the Parker Institute for Cancer Immunotherapy

view bio

Li ming

General Manager, Ping An Ventures

view bio